Stockhub

Instem plc: European Medicines Agency Research Grant: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

3 September 2022

2 September 2022

  • curprev 16:1916:19, 2 September 2022‎ 94.119.64.34 talk‎ 3,020 bytes +1‎ No edit summary undo Tag: Visual edit
  • curprev 15:5815:58, 2 September 2022‎ 94.119.64.4 talk‎ 3,019 bytes +3,019‎ Created page with "Announcement date: {{Date|3rd May 2022}} == Summary == Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that it has secured funding as part of a €2.5m European Medicines Agency ("EMA") grant - with the Company receiving c.12.5% of funds invested by the EMA. As part of an industry and academic consortium of nine beneficiaries, funded by EMA and led by Fraunhofer Institute for Toxicology and Experimental Medicine..."
Retrieved from ‘https://stockhub.co/research/Instem_plc:_European_Medicines_Agency_Research_Grant’